AU2003262937B2 - Adzymes and uses thereof - Google Patents

Adzymes and uses thereof Download PDF

Info

Publication number
AU2003262937B2
AU2003262937B2 AU2003262937A AU2003262937A AU2003262937B2 AU 2003262937 B2 AU2003262937 B2 AU 2003262937B2 AU 2003262937 A AU2003262937 A AU 2003262937A AU 2003262937 A AU2003262937 A AU 2003262937A AU 2003262937 B2 AU2003262937 B2 AU 2003262937B2
Authority
AU
Australia
Prior art keywords
adzyme
domain
protein
receptor
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003262937A
Other languages
English (en)
Other versions
AU2003262937A1 (en
Inventor
Noubar B. Afeyan
Brian Baynes
Ruchira Dasgupta
Frank D. Lee
Gordon G. Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2003262937A1 publication Critical patent/AU2003262937A1/en
Assigned to COMPOUND THERAPEUTICS, INC. reassignment COMPOUND THERAPEUTICS, INC. Amend patent request/document other than specification (104) Assignors: AFEYAN, NOUBAR B., COMPOUND THERAPEUTICS, INC.
Assigned to ADNEXUS THERAPEUTICS, INC. reassignment ADNEXUS THERAPEUTICS, INC. Request for Assignment Assignors: Compund Therapeutics, Inc.
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY Request for Assignment Assignors: ADNEXUS THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2003262937B2 publication Critical patent/AU2003262937B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003262937A 2002-08-27 2003-08-27 Adzymes and uses thereof Ceased AU2003262937B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40651702P 2002-08-27 2002-08-27
US60/406,517 2002-08-27
US42375402P 2002-11-05 2002-11-05
US60/423,754 2002-11-05
US43000102P 2002-11-27 2002-11-27
US60/430,001 2002-11-27
PCT/US2003/026937 WO2004019878A2 (en) 2002-08-27 2003-08-27 Adzymes and uses thereof

Publications (2)

Publication Number Publication Date
AU2003262937A1 AU2003262937A1 (en) 2004-03-19
AU2003262937B2 true AU2003262937B2 (en) 2009-05-07

Family

ID=31982336

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003262937A Ceased AU2003262937B2 (en) 2002-08-27 2003-08-27 Adzymes and uses thereof

Country Status (6)

Country Link
US (2) US20040081648A1 (cg-RX-API-DMAC7.html)
EP (1) EP1539941A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005537032A (cg-RX-API-DMAC7.html)
AU (1) AU2003262937B2 (cg-RX-API-DMAC7.html)
CA (1) CA2497047A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004019878A2 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
CA2416219C (en) 2000-07-11 2016-10-11 Research Corporation Technologies, Inc. Artificial antibody polypeptides
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
US20050074865A1 (en) * 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
WO2004031733A2 (en) * 2002-10-02 2004-04-15 Catalyst Biosciences Methods of generating and screenign for porteases with altered specificity
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US7790762B2 (en) 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
WO2005087947A2 (en) * 2004-03-09 2005-09-22 Meyer Pharmaceuticals Llc Bioengineered proteolytic enzymes with enhanced specificity for cytokine receptors
WO2005110453A2 (en) * 2004-04-12 2005-11-24 Catalyst Biosciences, Inc. Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
US20090042780A1 (en) * 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US20050281799A1 (en) 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
CA2570261C (en) 2004-07-08 2014-06-10 Pneumrx, Inc. Pleural effusion treatment device, method and material
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
US20080171067A1 (en) * 2007-01-17 2008-07-17 Immunomedics, Inc. Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites
AU2006264339A1 (en) * 2005-07-01 2007-01-11 Acceleron Pharma Inc. Lefty, Lefty derivatives and uses therof
WO2007030708A2 (en) * 2005-09-08 2007-03-15 Adnexus Therapeutics, Inc. Antimicrobial adzymes and uses thereof
WO2008048685A2 (en) * 2006-10-19 2008-04-24 Duke University Ox40 aptamers
CN101517086A (zh) 2006-07-21 2009-08-26 希乐克公司 生物质转化系统
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
US7680553B2 (en) * 2007-03-08 2010-03-16 Smp Logic Systems Llc Methods of interfacing nanomaterials for the monitoring and execution of pharmaceutical manufacturing processes
WO2009002607A1 (en) * 2007-05-01 2008-12-31 Dana-Farber Cancer Institute, Inc. Compositions and methods for identifying transforming and tumor suppressor genes
EP2247615B1 (en) 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
US20100099609A1 (en) * 2008-07-28 2010-04-22 Buck Institute For Age Research eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE
CN110187119B (zh) * 2008-10-31 2022-07-29 耶鲁大学 子痫前期检测和治疗的方法和组合物
CA3190837A1 (en) * 2009-01-15 2010-07-22 Glutagen Pty Ltd Compositions for the treatment of gluten intolerance and uses thereof
WO2011050263A2 (en) * 2009-10-23 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Systemic immunosuppression in the treatment of age related macular degeneration and diabetic retinopathy
ITBG20120050A1 (it) * 2012-10-29 2013-01-28 Michele Mutti Proteina di fusione con attività proteasica e specificità degli anticorpi
US20190343963A1 (en) * 2016-04-22 2019-11-14 Medimmune Limited Conjugated protease targeting moieties
AU2017340387A1 (en) * 2016-10-04 2019-05-02 University Of Florida Research Foundation, Inc. Targeted effector proteins and uses thereof
WO2019075062A1 (en) 2017-10-11 2019-04-18 University Of Florida Research Foundation MODIFIED GAL-1 PROTEINS AND USES THEREOF
WO2019222296A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2020087051A1 (en) 2018-10-26 2020-04-30 University Of Florida Research Foundation, Incorporated Targeted chondroitinase abc fusion proteins and complexes thereof
US12577282B2 (en) 2019-02-28 2026-03-17 University Of Florida Research Foundation, Incorporated Galectin-1/ galectin-3 chimeras and multivalent proteins
WO2025114429A1 (en) * 2023-11-29 2025-06-05 Intract Pharma Ltd Transcytosing composition

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
EP0355068A3 (en) * 1988-08-19 1991-09-04 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and their use
WO1991012328A1 (en) * 1990-02-15 1991-08-22 Fowlkes Dana M Totally synthetic affinity reagents
US5961973A (en) * 1992-03-06 1999-10-05 Crea; Roberto Pathogen-targeted biocatalysts
CA2086165A1 (en) * 1992-04-09 1993-10-10 Paul P. Tamburini Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein
US5997861A (en) * 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US6399355B1 (en) * 1995-06-07 2002-06-04 The Trustees Of Columbia University In The City Of New York Non-naturally occurring targeted lipolytic compounds and related compositions and methods
GB9618960D0 (en) * 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
DE19643314A1 (de) * 1996-10-21 1998-04-23 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen das Epitop YPYDVPDYA, Verfahren zu deren Herstellung und Verwendung
US6406846B1 (en) * 1997-10-14 2002-06-18 David Whitcomb Method for determining whether a human patient is susceptible to hereditary pancreatitis, and primers therefore
US6159722A (en) * 1997-12-03 2000-12-12 Boehringer Mannheim Gmbh Chimeric serine proteases
US6627744B2 (en) * 1999-07-02 2003-09-30 Genencor International, Inc. Synthesis of glycodendrimer reagents
CA2412664A1 (en) * 2000-06-15 2001-12-20 Board Of Regents The University Of Texas System Regulatable, catalytically active nucleic acids
CN100400101C (zh) * 2000-08-17 2008-07-09 特里帕普股份公司 包含病毒唑的疫苗及其使用方法
US20030068792A1 (en) * 2000-12-14 2003-04-10 Yiyou Chen Targeted enzymes
AU2002342672A1 (en) * 2001-09-11 2003-03-24 Nascacell Gmbh Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes

Also Published As

Publication number Publication date
EP1539941A2 (en) 2005-06-15
EP1539941A4 (en) 2006-11-29
JP2005537032A (ja) 2005-12-08
WO2004019878A3 (en) 2004-07-15
AU2003262937A1 (en) 2004-03-19
US20040081647A1 (en) 2004-04-29
WO2004019878A2 (en) 2004-03-11
CA2497047A1 (en) 2004-03-11
US20040081648A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
AU2005219878B2 (en) Adzymes and uses thereof
US20040081648A1 (en) Adzymes and uses thereof
JP6405311B2 (ja) 少なくとも2つの異なる実体を含む分子を作製および選択するための方法ならびにその使用
WO2024031046A2 (en) Il-18 fusion proteins and methods of producing il-18
US20040259155A1 (en) Methods of engineering spatially conserved motifs in polypeptides
JP2005537032A5 (cg-RX-API-DMAC7.html)
US20030228660A1 (en) Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries
JP2022524337A (ja) 腫瘍抗原を標的とするfc領域及び部分を含有する条件的に活性化された結合タンパク質
IL305716A (en) Activated garaged cytokine constructs and related compositions and methods
WO2001002440A1 (en) Fusion peptides comprising a peptide ligand domain and a multimerization domain
EP4704879A2 (en) Methods of using il-18 fusion proteins
Sears et al. Engineering enzymes for bioorganic synthesis: peptide bond formation
US20200172867A1 (en) Compositions and methods related to multimodal therapeutic cell systems for cardiometabolic disease
JPH05503631A (ja) 組換えポリペプチド類の精製法
WO2007030708A2 (en) Antimicrobial adzymes and uses thereof
US20240377394A1 (en) Cell Selection Methods and Related Compositions
JPH1175879A (ja) プロテインジスルフィドイソメラーゼを含有する融合タンパク質をコードするdna
CN120283055A (zh) 异多聚体蛋白质的制造方法、蛋白质、核酸、表达载体、转化体、以及蛋白质的制造方法
KR20250110226A (ko) 재조합 단백질 발현을 증가시키는 방법
AU752369B2 (en) TNF-alpha converting enzyme
HK40014351B (en) Method for selection and production of tailor-made targeting entities containing at least two different binding entities and uses thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: DELETE THE CO-APPLICANT AFEYAN, NOUBAR B.

TC Change of applicant's name (sec. 104)

Owner name: ADNEXUS THERAPEUTICS, INC.

Free format text: FORMER NAME: COMPUND THERAPEUTICS, INC.

PC1 Assignment before grant (sect. 113)

Owner name: BRISTOL-MYERS SQUIBB COMPANY

Free format text: FORMER APPLICANT(S): ADNEXUS THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired